• POAI positioned as leader in using data, artificial intelligence in search for novel effective treatments
• Planned acquisition provides Predictive Oncology with CoRE(TM), a proven machine-learning framework
• Uniting CoRE with proprietary PDx tumor-profiling platform and tumor-data database creates one-of-a-kind, end-to-end “discovery machine”

With its recent proposed acquisition of Carnegie Mellon spin-out Quantitative Medicine, Predictive Oncology Inc. (NASDAQ: POAI), a leader in using data and artificial intelligence (AI) to develop personalized cancer therapies, demonstrates its strong position in assisting in the search for new anti-cancers, anti-virals, antibiotics and vaccines. POAI’s expertise in this area is particularly relevant in light of the current race to learn more about the novel coronavirus 2019-nCoV and identify potential treatments, including vaccines, to fight the COVID-19 disease.

As organizations around the world rush to find ways to slow the spread of the COVID-19 outbreak, the importance of AI and machine learning (ML) in the world of today’s medicine has become increasingly clear (http://ibn.fm/wekHx). Governments, pharmaceutical companies, universities and others are united in their focus to develop new diagnostics, vaccines and drug therapies aimed at the 2019-nCoV virus.

Announcements from Insilico Medicine and MIT point to the increasing importance of AI and ML in the progress of modern medicine. In addition, both studies relied on AI and ML approaches that are similar to the CoRE technology used by QM, which POAI is working to acquire (http://ibn.fm/VVfym). With an agreement in principal in place, the all-stock acquisition is expected to close this month.

This planned acquisition provides POAI with QM’s proven machine-learning framework, called CoRE. Developed at CMU and exclusively licensed to QM, CoRE is a predictive model-building platform for drug screening and optimization campaigns that uses hybrid machine-learning approaches to rapidly build predictive models to drive wet-lab experimentation.

Uniting the CoRE approach with the proprietary PDx tumor-profiling platform and tumor-data database owned by POAI subsidiary Helomics allows for a one-of-a-kind, end-to-end “discovery machine” (http://ibn.fm/RHsQS). This approach will “rapidly and cost-effectively generate potential therapeutic candidates that demonstrate activity against the disease. Therapeutic candidates developed by this iterative AI and experiment cycle can be fast-tracked, since there is already demonstrated activity in preclinical laboratory tests rather than just a computer model.”

Although POAI’s current focus is on cancers, the CoRE discovery machine could easily be utilized in other critical research, including the rapid discovery of therapeutics, such as anti-virals. “Given sufficient resources and access to relevant data, POAI’s CoRE-driven Helomics discovery machine could soon be at the forefront of the fight against these new viruses,” POAI’s release noted.

The impact of this collaboration on the healthcare industry – between POAI’s AI expertise and QM’s CoRe platform – looms large. Insilico Medicine and MIT illustrate the critical part AI and ML play in the process of advancing modern medicine. In its announcement, Insilico Medicine shared molecular structures potentially to targeting the key protein of 2019nCoV. “By making these structures available to the general public, Insilico hopes those who are interested in finding a potential treatment for this viral infection could synthesize and test these molecules,” the announcement said (http://ibn.fm/yYhLv). Insilico will also “synthesize and test up to 100 molecules using its own resources and the resources generously offered by its closest partners, to contribute to the global effort.”

For its part, MIT used an MI algorithm to identify a powerful new antibiotic compound that “killed many of the world’s most problematic disease-causing bacteria, including some strains that are resistant to all known antibiotics,” MIT researchers announced (http://ibn.fm/0sxWn). “It also cleared infections in two different mouse models. The computer model, which can screen more than a hundred million chemical compounds in a matter of days, is designed to pick out potential antibiotics that kill bacteria using different mechanisms than those of existing drugs.” As healthcare industry leaders continue to harness the power of AI and ML technologies to improve patient outcomes, the demand for reliable, data-rich platforms like that of POAI is only expect to grow.

POAI is bringing precision medicine, or tailored medical treatment using the individual characteristics of each patient, to the treatment of cancer. Through its Helomics division, the company leverages its unique, clinically validated patient derived (PDx) smart tumor profiling platform to provide oncologists with a roadmap to help individualize therapy. In addition, the company is leveraging artificial intelligence and its proprietary database of over 150,000 cancer cases tumors to build AI-driven predictive models of tumor drug repose to improve outcomes for the patients of today and tomorrow.

For more information, visit the company’s website at www.Predictive-Oncology.com

NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI

• Pioneering supplier-to-pharmacy tech platform builder Trxade Group Inc. helps small, community-based pharmaceutical businesses be competitive with larger chains by sourcing drugs at discount prices and promoting transparency in business operations
• Trxade Group has been developing its subscribers’ access to licensed medical professionals through telehealth services that are both convenient to the patient and significant in their ability to limit the number of people visiting hospitals and offices
• Amid the sweeping, deadly impact of the seasonal flu and the rising novel coronavirus epidemic, Trxade’s online access to physicians is a timely preventative service
• Trxade Group Inc. recently announced its uplisting to the Nasdaq Capital Market and rang the exchange’s opening bell, changing its ticker from ‘TRXD’ to ‘MEDS’
• The company’s network of pharmaceutical partners continues to grow, serving a large percentage of the nation’s 24,000 independent pharmacies

Innovative B2B health services provider Trxade Group Inc. (NASDAQ: MEDS) is helping to reduce exposure to deadly viruses sweeping the planet through the patient empowerment actions of its wholly owned subsidiaries.

As seasonal flu virus infections continue to claim the lives of tens of thousands of Americans and hospitalizes hundreds of thousands of people worldwide (http://ibn.fm/svaWn), the rise and spread of the novel coronavirus COVID-19 has drawn attention to international measures to stop a deadly, vaccine-less illness by first locking down an entire province (in China), and most recently an entire nation (in Italy), while other communities worldwide close public gathering venues or attempt to assure attendees that adequate health measures are being taken to limit their exposure to such viruses (http://ibn.fm/8m08C).

Trxade Group’s support of community-based, independent pharmacies, as well as the acquisition of Community Specialty Pharmacy’s online access operation last year (http://ibn.fm/w1vWg) and the establishment of the “Bonum Health Hub” online portal initiative this year (http://ibn.fm/M2SBE) seems almost prescient in nature given the viral outbreaks’ impact even on access to hospital facilities and their providers (http://ibn.fm/HSCXs).

On March 10, Trxade Group announced the launch of a new membership service by its virtual healthcare subsidiary Bonum Health and its DelivMeds concierge medication delivery operation. The new service allows subscribers to obtain three premium medical teleconferencing visits and free prescription delivery per month, according to a company news release (http://ibn.fm/BDhhl).

Bonum’s telehealth services utilize patients’ personal smart tech devices in a private, HIPPA compliant manner that delivers access to board-certified physicians from virtually anywhere the patient may choose to be.

“Teleconferencing with a board-certified provider for assurance via online consultation is quick, easy, and relatively inexpensive. These services free patients from unnecessary exposure or resorting to urgent care facilities and hospital emergency rooms,” Trxade Group’s news release states. “With the seasonal flu outbreaks and the current coronavirus surge, patients are quick to brush off common symptoms, including cough, fever and body aches, as signs of a common cold; Telemedicine removes the barrier of self-doubt and complacency in the current climate of world-wide viral infections.”

Trxade Group is building a growing platform of integrated drug procurement, delivery and healthcare services to facilitate price transparency and increased profit margins for independent pharmacies within its network as well as pharmaceutical product sellers.

The company recently uplisted its common stock to the Nasdaq Capital Market, while also announcing it expected gross proceeds of $5.2 million from the sale of common stock in a public offering (http://ibn.fm/Nr5uo).

For more information, visit the company’s website at www.TrxadeGroup.com

NOTE TO INVESTORS: The latest news and updates relating to MEDS are available in the company’s newsroom at http://ibn.fm/MEDS

• InsuraGuest Technologies provides travel lodging insurance designed as a stop-gap measure to protect travelers and the establishments where they stay in cases where existing policies may not provide coverage
• The company resumed trading on the TSX Venture Exchange on Friday, Feb. 28 at the market’s opening
• InsuraGuest’s ticker will now be ISGI, following a capital consolidation resolution approved by shareholders in November that has been accepted by the TSX exchange
• InsuraGuest is expanding the reach of its proprietary technology throughout the United States, Europe and the United Kingdom, with expectations to enter Asia in mid-2020
• InsuraGuest’s policy, underwritten by Crum & Forster companies, provides first-response protection in cases of in-room property damage, lost or stolen goods, accidental medical expenses, and accidental death and dismemberment at the lodging site up to the policy limits

Supplemental travel accommodations insurance provider InsuraGuest Technologies Inc. (TSX.V: ISGI) resumed trading on the TSX Venture Exchange at the market’s opening on Friday, February 28, under ticker symbol ‘ISGI’.

The name change and consolidation of capital follows a resolution voted on by shareholders at a special meeting held November 29 in which the shareholders approved the company’s acquisition of all of InsuraGuest’s shares for a consideration of 21,080,992 shares, 5,180,000 replacement warrants, 30,354,635 performance warrants and 700,000 options of the company, which the TSX exchange has accepted (http://ibn.fm/1EPIP).

InsuraGuest has been expanding the reach of its proprietary insurtech software platform nationwide in the United States, has entered Europe and the United Kingdom, and expects to launch into Asia by mid-year in 2020. Its platform is adaptable to technology used by the industry’s players, ensuring coverage is governed by a single software system.

The company’s technology is designed to help sustain the travel lodging industry, providing a specialized Hospitality Liability insurance coverage policy to businesses such as hotels, vacation rentals and Airbnb-type residences that are redefining how travelers and tourists take care of their sleep and comfort needs while away from home.

InsuraGuest’s Hospitality Liability policy is a stop-gap product sold to the lodging facility and then included with the facility’s services provided to the customer for a nightly fee. It offers a first line of defense for both the property and the guest in case of personal property theft in the lodging site, as well as accidental in-room damage, accidental medical expense, and accidental death and dismemberment while at the site up to the policy limits, as underwritten by Crum & Forster companies.

Travelers may otherwise find that property owners’ short-term rental insurance policies don’t protect the property’s guests, or that their own travel insurance and homeowner policies fall short of their needs away from home. Airbnb offers a $1 million property damage coverage policy to its sites, but a number of customers have argued in lawsuits that the company has fallen short of its obligations when the need arose (http://ibn.fm/BKvoD).

“Currently, the biggest issue in the vacation rental industry is about standards, and safety and security compliance. Until now, there has been very little guidance for property managers and owners as to how to operate their properties with best practice when it comes to guest safety and security,” Canadian rental certification business founder Wolf Wörster stated in a Viva Glam magazine article on the industry (http://ibn.fm/pVHof).

For more information, visit the company’s website at www.InsuraGuest.com

NOTE TO INVESTORS: The latest news and updates relating to ISGI are available in the company’s newsroom at http://ibn.fm/ISGI

• Leadership team brings collaborative experience from technology, finance and social-media giants
• After products achieve top-selling status, PLUS moves forward into new nationwide markets
• PLUS products available in more than 360 licensed retailers across California; set to launch new wellness/relief and recreational categories for 2020

Offering some of the best-selling cannabis products found in California, Plus Products Inc. (CSE: PLUS) (OTCQX: PLPRF) continues to make gains in achieving its goal of becoming the top brand in cannabis-infused products. With a world-class management team drawing on valuable experience working with top firms like Facebook, UBS, Uber, the Wonderful Company & Popchips, the company continues to balance rapid expansion and risk management – all while maintaining focus on building a brand, developing customer loyalty and securing a top position in the hyper growth cannabis industry.

The PLUS leadership team spans a wide range of expertise, work experience and industry exposure. After working at Facebook, CEO Jake Heimark co-founded PLUS. Chief strategy officer Craig Heimark lends high-powered finance expertise to the company gained from his experience at UBS and other similar firms. Managing the company’s finances is CFO Jon Paul, who brings more than 25 years of CFO experience to the team.

Navigating the constantly changing legal framework is chief risk officer Jennifer Tung, utilizing skills and expertise gained from her time spent at Uber and Facebook. Chief Scientific Officer Ari Mackler brings product knowledge to the company from his role as VP of clinical development at the Wonderful Company, as well as his PhD in neuroendocrinology.

Expert collaboration is a mainstay of the PLUS team. A collection of some of the best minds in the industry, the entire PLUS team works creatively to fulfill the company’s vision of dominating the cannabis edibles space by becoming the world’s largest cannabis brand.

The expert management team is combined with an exciting outlook for the space. PLUS’s first objective of developing a winning strategy in California was met with massive success when two of the company’s cannabis gummy products reached top-selling status less than two years after legalization. The company’s continuing strategy to become the world’s strongest cannabis-brand portfolio is moving forward through PLUS’ focused efforts to increase national presence, open up new markets of users and create new products for different needs.

PLUS products are now available in more than 360 licensed retailers across the state of California. The company also recently launched its products in Nevada, one of the nation’s most promising cannabis markets. Two new product offerings in two new categories – wellness/relief and what the company calls “get high/have fun” – are expected to launch in early 2020 as the next strategic step in PLUS’s plan to grow its product portfolio.

For more information, visit the company’s website at www.PlusProducts.com

NOTE TO INVESTORS: The latest news and updates relating to PLPRF are available in the company’s newsroom at http://ibn.fm/PLPRF

• Sigma Labs, Materialise joint sales agreement calls for product commercialization
• Earlier MOU outlined integration of Materialise MCP Controller, SGLB PrintRite3D(R) technology
• Exclusive product expected to lower additive manufacturing costs, improve yield and profit margin, lead to closed loop control

Sigma Labs Inc. (NASDAQ: SGLB), the only provider of in-process, quality-assurance software to the commercial 3D-metal- printing industry, has entered into a joint sales agreement with Materialise, a leading provider of additive manufacturing software and sophisticated 3D-printing services (http://ibn.fm/VwQX1).

An earlier memorandum of understanding provided a framework for the two companies to cooperate on the integration of the widely used Materialise MCP Controller with Sigma Labs’ PrintRite3D(R) technology, together creating an integrated PrintRite3D and Materialise Control Platform (MCP) product. The companies have now achieved integration and will begin offering a unique product solution for retrofit of existing machines, OEM machine integration and closed loop control. Commercialization of the 3D printing industry’s first in-process quality control software is expected to commence immediately.

“Growing our partnership with Materialise is a significant milestone for Sigma Labs as we expand our footprint in the market and add momentum to our quest to broaden industry access to our groundbreaking PrintRite3D software,” SGLB Executive Chairman Mark K. Ruport stated in a news release. “The alignment is a natural step for both companies, as Materialise has a strong presence in the additive manufacturing market and a reputation for quality products. Commercializing and jointly selling this integrated solution will benefit both companies as well as advance the forward momentum of innovation in the 3D-manufacturing industry.”

SGLB scientists, engineers and software developers developed proprietary hardware and software technology that uses thermal readings to detect and predict anomalies during the 3D-printing process. This technology, incorporated in Sigma Labs’ PrintRite3D software, features real-time monitoring, analysis, feedback and control that delivers impressive results.

When utilizing the software, end users can lower their additive manufacturing costs and improve yield and profit margin. The MCP is an embedded hardware and software solution that addresses the growing need for broader and more straightforward control over the additive manufacturing process by giving full control to the end-user.

Materialise brings together three decades of 3D-printing experience into a range of software solutions and 3D-printing services, which together form the backbone of the 3D-printing industry. Materialise’s open and flexible solutions enable players in a variety of industries, including healthcare, automotive, aerospace, art and design, and consumer goods, to build innovative 3D-printing applications designed to make the world a better and healthier place. Headquartered in Belgium with branches worldwide, Materialise combines the largest group of software developers in the industry with one of the largest 3D-printing facilities in the world.

Founded in 2010, Sigma is a software company that specializes in the development and commercialization of real-time, computer-aided-inspection (CAI) solutions known as PrintRite3D for 3D-advanced manufacturing technologies. SGLB’s advanced, computer-aided software product revolutionizes commercial additive manufacturing, enabling nondestructive quality assurance mid-production, uniquely allowing errors to be corrected in real time.

For more information about Sigma Labs, please visit www.SigmaLabsInc.com

NOTE TO INVESTORS: The latest news and updates relating to SGLB are available in the company’s newsroom at http://ibn.fm/SGLB

• Cannabis Global, an innovator in cannabis-infused product science, has launched new coffee and alcohol-replacing products under its Hemp You Can Feel brand since the beginning of the year
• The company promotes the safety and wellness benefits derived from introducing cannabinoids into the food and beverage industry
• A recent report by American Marijuana and a 2018 report by SAMHSA combine to show the importance of using cannabinoid legalization to combat opioid overdoses
• American Marijuana’s study found that of 19 states where medical marijuana is legal, 15 saw marked reductions of opioid prescriptions during the first year after the cannabinoids’ legalization

MCTC Holdings Inc. (OTC: MCTC), now doing business as Cannabis Global, continues to roll out cannabis-infused products designed to revolutionize the food and beverage industry even as news reports continue to highlight the benefits of cannabis in reducing the rate of opioid prescriptions and their potentially harmful addictions.

Cannabis Global’s branded Hemp You Can Feel (TM) Coffee made its debut Feb. 26 in Las Vegas as a science-based infused coffee beverage alternative for advancing wellness-boosting properties, and the company will hold a Hemp You Can Feel Alcohol-Free cocktails launch event for the media in Los Angeles on March 12.

Cannabinoid extracts such as cannabidiol (CBD) and tetrahydrocannabinol (THC) are touted for their ability to deliver pain and anxiety relief through a variety of media, and Cannabis Global’s research continues to explore mechanisms for enhancing their bioavailability.

A recent report by American Marijuana notes that the legalization of medical marijuana throughout the United States has correlated with a reduction in the amount of opioid painkillers being prescribed.

“We’ve selected 19 states where medical marijuana is legal then compared the opioid prescribing rate 1 year before and after medical marijuana was legalized in the state,” the article states (http://ibn.fm/vL9Hd). “Out of the 19 states, 15 have shown a fall of opioid prescribing rate 1 year after legalization of medical marijuana, and only 4 have increased in usage, namely: New Jersey, New Mexico, Michigan, and Arizona.”

The article states Ohio reported the largest drop in the opioid prescription rate, from 82.7 percent to 63.5 percent, measuring the rate of retail opioid prescriptions dispensed per 100 people per year.

Pennsylvania followed Ohio’s 19.2 percent drop with its own 17.8 percent decline in opioid prescriptions, with Arkansas coming in next at 11.8 percent and North Dakota at 11.5 percent. None of the four states with increasing use saw double-digit gains – Michigan, the highest, reported a 9 percent increase while New Jersey was the lowest with a 1.9 percent increase.

The report also noted a study’s findings that Medicaid recipients saw a decrease in opioid prescriptions with the legalization of adult-use recreational marijuana and medical marijuana in their states.

The burgeoning availability of opioid prescription pain relievers such as hydrocodone and oxycodone have been linked to escalating drug addictions during recent decades. The Substance Abuse and Mental Health Services Administration (SAMHSA) reported in its 2018 National Survey on Drug Use and Health that approximately 10 million people aged 12 or older misused opioids in 2018, whether under prescription or in combination with illicit drug, and that about 400,000 died from prescription opioid and related illegal drug overdoses between 1999 and 2017 (http://ibn.fm/ETUDu).

“Can Cannabis solve the opioid crisis? Short answer, to us, is it CAN be a part of the solution to the crisis,” the American Marijuana article states.

Global Cannabis CEO Arman Tabatabaei also touts the safety benefits of using cannabinoids as a replacement for alcohol to avoid the negative effects on behaviors associated with alcohol.

“We believe the uses for this advanced infusion technology are many, especially as a replacement for alcohol in various beverages,” Tabatabaei stated in a December news release (http://ibn.fm/4km21).

For more information, visit the company’s website at www.CannabisGlobalInc.com

NOTE TO INVESTORS: The latest news and updates relating to MCTC are available in the company’s newsroom at http://ibn.fm/MCTC

• Dan Handley brings wealth of invaluable experience to POAI’s board of directors
• Newest board member has extensive experience with entities closely associated with POAI’s Helomics division
• Predictive Oncology set to benefit from Handley’s broad knowledge, expertise

Predictive Oncology Inc. (NASDAQ: POAI), a leader in the cancer precision-medicine field, has announced the unanimous appointment of its newest board member (http://ibn.fm/bK1Pr). Dr. Dan Handley, MS, PhD, brings a wealth of invaluable experience to POAI’s already impressive board of directors.

“Predictive Oncology is once again very fortunate to announce another exemplary addition to our Board of Directors,” POAI CEO Dr. Carl Schwartz stated in a news release. “Dan Handley has a varied and strong background, including interaction with Carnegie Mellon University and Magee-Women’s Research Institute – both leaders in their respective fields and closely associated with our Helomics division. I greatly anticipate working with Dan and benefitting from his knowledge and experience.”

Currently serving as a professor and the director of the Clinical and Translational Genome Research Institute of Southern California University of Health Sciences, Handley has also served as chief scientific officer of the Clinical and Translational Genome Research Institute, a Florida 501(c)3 nonprofit corporation. During his time at the Genome Research Institute, Handley held a courtesy faculty appointment in the Department of Biological Sciences at Florida Gulf Coast University.

Other roles Handley has filled include chief scientific officer for Advanced Healthcare Technology Solutions Inc.; senior researcher at Procter & Gamble; senior administrator, researcher and laboratory manager at the David Geffen UCLA School of Medicine; and a founding biotechnology inventor for the National Genetics Institute.

Handley holds a BA in biophysics from Johns Hopkins University, an MS in logic and computation from Carnegie Mellon University and a PhD in human genetics from the University of Pittsburgh. In addition, he completed his postdoctoral training at Magee-Women’s Research Institute where his research focused on advanced genomic technologies applied to fetal and maternal health. A decorated veteran, Handley served as a nuclear propulsion instructor and a submarine nuclear reactor operator during his time with the U.S. Navy.

POAI is bringing precision medicine, or tailored medical treatment using the individual characteristics of each patient, to the treatment of cancer. Through its Helomics division, the company leverages its unique, clinically validated patient derived (PDx) smart tumor profiling platform to provide oncologists with a roadmap to help individualize therapy. In addition, the company is leveraging artificial intelligence and its proprietary database of over 150,000 cancer cases tumors to build AI-driven models of tumor drug repose to improve outcomes for the patients of today and tomorrow.

For more information, visit the company’s website at www.Predictive-Oncology.com

NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI

• Ceylon Graphite commences production of the world’s purest natural graphite: required component of widely used lithium-ion batteries
• Named Asia Pacific Exploration Mining Company of Year in 2018, company holds one of only four A-category licenses for mining graphite in Sri Lanka, world’s most graphite-rich region
• CYL represents a high potential investment backed by global demand for graphite that enables production of vast number of products globally

Ceylon Graphite (TSX.V: CYL), a company specializing in the exploration and production of graphite in Sri Lanka – where it holds a land package of 121 km² with grids containing unique and comparatively higher-margin vein graphite deposits – is on track to becoming a global player in the sector as it has commenced the production of the world’s purest graphite. CYL operates through two wholly owned subsidiaries, Sarcon Development (Pvt) Ltd. and JADS Enterprises (Pvt) Ltd. At the end of 2019, Sarcon Development (Pvt) Ltd. started commercial production – a step the company described as a milestone towards creating a globally recognized graphite mining company with the capacity to develop the next sites and at a faster pace.

International demand for graphite is robust and expected to increase. With the global trend of the decarbonization of the energy storage and transportation sector gaining increasing traction, graphite has been named the “new oil.” The growing demand is supported by the needs of energy storage equipment production, as well as high-quality batteries, lubricants, and refractories. CYL’s product is certified as battery grade marketable as the company produces some of the purest natural graphite on the planet.

With a strong management team leveraging their significant local and Asian experience and excellent business relationships, the company operates some of the cheapest and quickest-to-market natural graphite facilities in the world, which are geographically well-positioned for the Eastern markets such as China, Japan, and Korea. In 2018, the company was named ‘Asia Pacific Mining Exploration Company of the Year 2018’ by Mines and Money (http://ibn.fm/NAutl).

The company’s industry leadership is evidenced in its Sri Lanka operations. Ceylon Graphite operates the largest land package in the country with significant evidence of past production dating back to Sri Lanka’s stint as the world’s biggest graphite producer – an excellent indicator of the presence of graphite. The company runs four sites with different degrees of completion. Last year the company’s subsidiary, Sarcon Development (Pvt) Ltd., was granted an industrial mining license category A for its K1 project at Karasnagala from the mining regulator in Sri Lanka. This is a considerable achievement as the graphite industrial mining license category A was issued only four times since the country’s independence in the ‘60s. This highest category license grants exclusive rights to mine, process, and trade in graphite mined within the specified area (http://ibn.fm/fg3v9).

CYL is focused on commercial production, constructing processing plants, and establishing long term sales contracts and joint ventures with battery and energy storage equipment manufacturers. It is expected that lithium-ion battery anode requirements will be the main driving force behind the demand for natural graphite. This production, however, requires high purity graphite – a minimum of 99.95% Cg – which CYL is capable of delivering. Its graphite can achieve 99.9997% Cg purity level (http://ibn.fm/6nBoC). Not only has the company achieved high-purity graphite results, it did so utilizing an environmentally responsible and sustainable thermal purification process devoid of dangerous and environmentally harmful acids – placing CYL at the forefront of the global graphite production map (http://ibn.fm/Tq0Cf).

With its capacity to deliver high-grade natural graphite, CYL is well-positioned to capitalize on the robust demand driven by the needs of production of electric vehicles and lithium-ion batteries for consumer electronics such as mobile phones, laptops, tablets, and media players. Li-ion batteries are present in over 90% of modern electronic devices, with 10 to 20 times more graphite then lithium-ion. Given the broad application of the natural graphite and its utilization in products that consumers and businesses are becoming increasingly dependent upon, the opportunities for market growth are vast. In this market, however, CYL has a unique position as the competition delivers significantly lower purity of natural graphite.

With production aimed at positioning the company as a global player, CYL is an attractive opportunity that will benefit investors with high growth potential on the tail of the robust international demand for natural graphite.

For more information, visit the company’s website at www.CeylonGraphite.com

• Company uses strategic agreements, acquisitions, and intellectual property to achieve multiple growing verticals within global cannabis industry
• U.S. hemp industry has seen massive growth since 2018 Farm Bill legalized industrial hemp
• Experts predict CBD sector will reach $20 billion in 2024

MCTC Holdings Inc. (OTC: MCTC), a cannabinoid science innovator (dba Cannabis Global), is positioned at the cutting edge of the industry’s trends with its focus on polymeric nanotechnology designed to maximize bioavailability. The company plans to market and license multiple polymeric cannabinoid nanoparticle and nanofiber-based products that will offer enhanced bioavailability and release properties as well as advanced customization options. As polymer-based particles offer significant loading of active ingredients and increased flexibility and customization, MCTC believes this will allow for multiple cannabinoid combinations with unique features.

Recently, the company filed six patents (all six patents are pending approval with USPTO), of which its fourth cannabinoid delivery technology patent is the most important for cannabinoid delivery systems. This patent broadly covers many aspects of nanoparticles and nano fibers comprising one or more cannabinoids disposed at least partially within a water-soluble medium (http://ibn.fm/ggZWA).

The company’s sixth patent also pertains to delivery systems — it is for a unique dosing system that makes it possible for any manufacturer of coffee pods to add cannabinoids or other active ingredients to coffee pods with ease.

“The patent filing broadly outlines a variety of methods and technologies to be used for adding cannabinoids to single-serving coffee pods. With our system, any manufacturer of coffee pods can now produce CBD or other coffee pods with simple modification to their processes. The patent filing represents growth of our intellectual property to include broader systems for cannabinoid delivery,” MCTC CEO Arman Tabatabaei stated in a news release (http://ibn.fm/yDVqd).

Through 2020, the company plans to conduct trials on exotic and lesser-known cannabinoids like cannabinol (CBN) and THC-V, including their potential effects on appetite suppression. MCTC is also working with patent counsel to protect various other aspects of its other new technologies. The company has announced a new research project named THC-V Skinny Cannabinoid Project Varin for THC-V infusions, nanoparticles, and glycosides.

The company’s flagship beverage product line, Hemp You Can Feel(TM) is an organic, ultra-clean label line of CBD powdered drink and hemp extract mixes, including soft beverages and non-alcoholic cocktail mixers. It is carefully manufactured via a closely monitored production process from start to finish. The green coffee beans are imported, roasted, and ground on site. The product is infused with only hemp extracts, honey from organic farms, organic non-GMO starches from vegetables, and trace amounts of organic vegetable and coconut oils, a fact reflected in the price and quality of their products. The manufacturing method used is an innovative two-stage hemp extract infusion process currently Patent Pending with the U.S Patent and Trademark Office.

Hemp You Can Feel(TM) is 100% compostable within 120 days of being discarded properly. This includes the packaging, the lid, the coffee pod, and the package inserts. Each coffee pod contains at least 30 milligrams of CBD, a large number of additional hemp extract components, and no detectable THC (http://ibn.fm/PBVz3).

MCTC recently signed a distribution contract with Marijuana Company of America (OCTQB: MCOA) for the Hemp You Can Feel(TM) beverage product line and plans to extend the collaboration to other drink offerings to be introduced soon (http://ibn.fm/IuY7A). As MCOA specializes in delivering renowned brands through distributors and unique marketing strategies, the agreement is expected to bring added visibility to MCTC’s products.

As an integrated cannabis business operation and cannabinoid science innovator, MCTC Holdings is primarily focused on high-growth and high-margin sub-sectors of the cannabis and hemp industry, including multiple growing verticals in the global cannabis and industrial hemp markets via acquisitions, partnerships and the development of new intellectual property.

The U.S. hemp industry has seen massive growth since the 2018 Farm Bill legalized the cultivation of industrial hemp. The sector was worth millions just a year after federal legalization, augmented by the demand for hemp-derived CBD. According to research from BDS Analytics and Arcview Market Research, the U.S. CBD market is expected to reach $20 billion in sales by 2024 (http://ibn.fm/fGdK6). Meanwhile, the global industrial hemp market is poised to grow exponentially as well — from $4.6 billion in 2019 to $26.6 billion by 2025, recording a CAGR of 34%, as indicated by a Research and Markets report (http://ibn.fm/jSBIt).

For more information, visit the company’s website at www.CannabisGlobalInc.com

NOTE TO INVESTORS: The latest news and updates relating to MCTC are available in the company’s newsroom at http://ibn.fm/MCTC

• SHRG announces successful presale launch of new product called ElevaciTea(TM)
• Company disrupting $80 billion U.S. coffee market with world’s first “happy coffee”
• Pursuit of happiness is hot 2020 trend; Sharing Services well-positioned with its business of elevating lives

Sharing Services Global Corporation (OTCQB: SHRG), a diversified holdings company dedicated to elevating the lives of entrepreneurs and clients, announced the release of its newest product called ElevaciTea(TM), available through its subsidiary Elevacity LLC (http://ibn.fm/ZfakV). This first-of-its kind, limited edition, vanilla-chai nootropic tea joins the company’s existing lineup of functional beverage offerings. Moreover, SHRG CEO John “JT” Thatch shared that the product’s two-day presale eclipsed all of SHRG’s prior product launches (http://ibn.fm/0Pzb0).

ElevaciTea, also called Happy Tea, is the newest product in Elevacity’s nootropic line. Nootropics are an all-natural blend of amino acids, choline and fat burners believed to improve cognitive function such as memory, creativity and/or motivation in healthy individuals. Elevacity promotes its nootropics line as an optimal formula to help deliver and elevate happiness hormones. This new tea is joining the company of a hot chocolate, a lemon-lime flavored drink, and two coffee options.

Elevacity products are sold by Elepreneurs, a growing international network of home-based entrepreneurs. Elepreneurs do not compete in the traditional direct-selling market but rather work to make competitors irrelevant, thereby succeeding in an uncontested marketplace. By selling the world’s first and only ‘happy coffee’, the company is disrupting an $80 billion U.S. coffee market that has seen substantial growth in the last two years (http://ibn.fm/bCdtX).

Those who choose to become an Elepreneur with Sharing Services commit to helping others elevate their health, wealth and happiness and, by doing so, elevate their own (http://ibn.fm/FSaeS).

Part of Sharing Services’ success is likely tied to one of this year’s hottest trends — the pursuit of happiness. For the last nine years, Shutterstock has run an annual creative trends report analyzing global and local trends that influence design aesthetics and visual culture for the coming year. The findings of 2020’s annual report yielded good news for Elevacity.

“This year’s data points toward the pursuit of meaning, happiness and opportunity in new creative projects – traits that may be reflective of the uncertainty in our climate and the year ahead,” Lou Weiss, chief marketing officer at Shutterstock, told WWD (http://ibn.fm/eQRw5).

The pursuit of happiness is on the rise. With so much negativity in the news and in the world, people want to reach for a cup of happiness. Whether through products or well-trained Elepreneurs dedicated to bringing happiness and wholeness to those they serve, Sharing Services and its Elevacity products are meeting the needs of 2020 and beyond.

For more information, visit the company’s website at www.SHRGInc.com

NOTE TO INVESTORS: The latest news and updates relating to SHRG are available in the company’s newsroom at http://ibn.fm/SHRG